ExeVir

TLDR

ExeVir develops novel antibody therapies using camelid antibody fragments to prevent and treat infectious diseases including COVID-19 and dengue.

Overview

ExeVir is a clinical stage company that develops antibody therapies using a modular platform technology based on single domain antibody fragments (VHH). The platform creates therapeutic compounds capable of binding multiple epitopes on viral particles, designed to address emerging infectious disease variants. The company focuses initially on COVID-19 and dengue to help vulnerable patients including the immunocompromised.